Hologic, Inc. (HOLX - Free Report) and Varian Medical Systems, Inc. (VAR - Free Report) are solid contenders in the U.S. MedTech space, which is expected to reach $409.5 billion worth by 2023 at a CAGR of 4.5%. Analysts believe that 2019 will prove profitable for the U.S. medical device companies, courtesy of a 2.3% Medical Device tax abatement along with focus on AI and cybersecurity.
Meanwhile, it is difficult to make a choice between the above-mentioned Medical instrument companies as both currently carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
However, we make a detailed analysis of the companies’ fundamentals to determine which has a slight edge over the other.
Massachusetts-based Hologic develops, manufactures and supplies diagnostics, medical imaging systems and surgical products, which cater to healthcare needs of women. The company is focused on building mammography systems for breast examination and osteoporosis assessment. Meanwhile, California-based Varian Medical Systems is the world’s leading provider of radiotherapy, radiosurgery, proton therapy and brachytherapy for treating cancer and other medical conditions. It is also a premier supplier of X-Ray tubes for medical, scientific and industrial applications.
Over the past year, Hologic’s shares have gained 22.8% compared with Varian Medical’s 7.9% rally. The Medical Instruments industry has grown 5.3% in the same time frame. Meanwhile, the S&P 500 index rose by 1.4%.
Which Way are Estimates Headed?
The Zacks Consensus Estimate for Hologic’s current-year earnings stands at $2.41, suggesting an improvement of 8.1% year over year. The same for Varian Medical is projected at $4.7, showing year-over-year growth of 6.3%.
The Zacks Consensus Estimate for Hologic’s current-year revenues is pegged at $3.32 billion, suggesting growth of 3.2% from the previous year. The same for Varian Medical is pegged at $3.12 billion, reflecting rise of 7%.
What’s Favoring these Stocks?
Hologic raised its fiscal 2019 guidance. The company now expects adjusted revenues of $3,305-$3,335 million compared with $3,290-$3,335 million stated previously (growth rate of 3.8-4.7% compared with 2.8-4.2% at CER). The company envisions adjusted EPS of $2.39-$2.43 compared with $2.38-$2.42 stated previously (marking a growth rate of 7.2-9.0% compared with 6.7-8.5%).
Meanwhile, Varian Medical kept its guidance for fiscal 2019 intact. For fiscal 2019, year-over-year revenue growth is expected to be $3.06-$3.15 billion, up 5-8%. Adjusted net earnings per share are expected to be $4.60 to $4.75.
Hologic’s management is impressed with continued growth in the core Molecular Diagnostics sub-segment, which accounted for roughly 55.4% of total Diagnostics revenues in the fiscal first quarter. The company is experiencing global growth on expanding market share and utilization of fully-automated Panther system along with continued solid uptake of Aptima women's health products. Per management, the company has more than 15 FDA-cleared or CE-marked tests to run on the Panther or Panther Fusion platforms.
Meanwhile, Varian Medical’s strong overseas presence is expected to enable it to leverage this opportunity in emerging markets. Precisely, the company’s Oncology Systems segment has been making noteworthy progress worldwide. In Asia, Varian Medical received orders for eight systems from the Philippines Department of Health. The company also opened a manufacturing facility in Jundiai, Brazil and delivered its first locally manufactured TrueBeams to Oncoclinicas in the country.
Over the past four years, Hologic’s revenues have seen a CAGR of 19% to $3.22 billion. Meanwhile, Varian Medical’s revenues witnessed a CAGR of 17.2% to $2.92 billion.
The above analysis shows that despite being close contenders, Hologic scores higher than Varian Medical when it comes to growth projections and fundamentals.
A few other top-ranked stocks in the broader medical space are Integer Holdings Corporation (ITGR - Free Report) and Veeva Systems Inc. (VEEV - Free Report) .
Integer Holdings projects earnings growth rate of 31.2% for the first quarter. It currently carries a Zacks Rank #1.
Veeva Systems’ long-term earnings growth rate is projected at 14.8%. The stock presently has a Zacks Rank #2.
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, wouldn't you like to know about our 10 finest buy-and-holds for the year?
From more than 4,000 companies covered by the Zacks Rank, these 10 were picked by a process that consistently beats the market. Even during 2018 while the market dropped -5.2%, our Top 10s were up well into double-digits. And during bullish 2012 – 2017, they soared far above the market's +126.3%, reaching +181.9%.
This year, the portfolio features a player that thrives on volatility, an AI comer, and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs.
See Stocks Today >>